Status:
COMPLETED
Effects of Rapid Genetic Counseling and Testing in Newly Diagnosed Breast Cancer Patients
Lead Sponsor:
The Netherlands Cancer Institute
Collaborating Sponsors:
UMC Utrecht
Fonds NutsOhra
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
5-10% of breast cancer patients carry a mutation in the BRCA1 or BRCA2 gene. Genetic counseling and DNA testing are usually offered to selected patients after primary treatment has been completed (e.g...
Detailed Description
In the Netherlands, approximately 12,000 women are diagnosed with breast cancer annually, of whom about 5-10% carry a mutation in the BRCA1 or BRCA2 gene. Genetic counseling and DNA testing are usuall...
Eligibility Criteria
Inclusion
- newly diagnosed breast cancer
- 10% or higher chance of carrying BRCA1/2 gene mutation
Exclusion
- age \<18 years
- does not speak Dutch
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
265 Patients enrolled
Trial Details
Trial ID
NCT00783822
Start Date
November 1 2008
End Date
March 1 2012
Last Update
November 9 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Amsterdam, Netherlands